Trends in Pharmacological Sciences
Research FocusNeuroprotection by tetracyclines
Section snippets
Molecular and cellular mechanisms of neuroprotection by tetracyclines
Tetracyclines prevent cell death in a wide range of in vitro and in vivo models by at least two mechanisms: attenuation of innate and adaptive immunity and blockade of apoptotic cascades (Figure 1). The CNS is an immune-privileged tissue, exhibiting a robust innate immune response that is mediated by microglia. Activation of microglia, a common feature of most neurodegenerative diseases, leads to the release of pro-inflammatory mediators and other injury response factors that ultimately
Tetracycline-mediated protection in models of acute neurodegeneration
Acute insults to the CNS such as ischemia, trauma or spinal cord injury cause immediate primary damage and a subsequent secondary degenerative response that develops over several days post-injury. This secondary response is amenable to therapeutic intervention and is characterized by inflammation and delayed neuronal death. Minocycline and doxycycline markedly reduce the size of infarction in both focal and global transient ischemia in the adult rat 1, 2, 7, 16 (Table 1). By contrast,
Tetracycline-mediated protection in models of chronic neurodegenerative diseases
Neuroprotection by tetracyclines in animal models of chronic neurodegenerative disorders has been associated with the anti-inflammatory and anti-apoptotic properties of tetracyclines (Table 1). In ALS transgenic mice, administration of minocycline delays the onset of disease and slows its progression. Moreover, it increases motor performance and extends survival by 2–3 weeks compared with non-treated ALS transgenic mice 13, 23. In addition, minocycline attenuates loss of
Therapeutic prospects of tetracyclines
Together, the studies described in this article indicate that minocycline and doxycycline are solid candidates for the treatment of major neurodegenerative diseases. Moreover, both of these tetracyclines readily cross the blood–brain barrier regardless of the dose and route of administration [30]. However, the dose of minocycline required to elicit neuroprotection in the absence of undesirable side-effects remains a crucial issue because in most experimental models the dose required can be as
Concluding remarks
The neuroprotective nature of tetracyclines is now well established. Recent studies have contributed greatly to our understanding of the molecular and cellular mechanisms that underlie neuroprotection mediated by these bacteriostatic agents. In addition, the protective properties of these molecules have been extended to oligodendrocytes and to white matter as a whole, emphasizing the relevance of these regions for the clinical consequences of brain and spinal cord damage. The safety and
Acknowledgements
We thank A. Verkhratsky, D.J. Fogarty, G. Linazasoro, F. Pérez-Cerdá and J.M. Delgado for critical reading of the manuscript. We also are grateful to the Gobierno Vasco, the Universidad del País Vasco, the Fundació La Caixa and the Ministerio de Sanidad y Consumo for funding support. M.D. holds a fellowship from the Gobierno Vasco.
References (30)
Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria
J. Biol. Chem.
(2004)Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model
Exp. Neurol.
(2004)The link between excitotoxic oligodendroglial death and demyelinating diseases
Trends Neurosci.
(2001)Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis
Neurobiol. Dis.
(2002)Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection
Exp. Neurol.
(2004)Reduction of central nervous system reperfusion injury in rabbits using doxycycline treatment
Stroke
(1994)Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Proc. Natl. Acad. Sci. U. S. A.
(1998)Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis
Neurology
(2004)Minocycline in Huntington's disease: a pilot study
Mov. Disord.
(2004)Minocycline safety and tolerability in Huntington disease
Neurology
(2004)